

REMARKS

Claims 15-17 are proposed to be amended, by replacing "monohydrate" in the second line of each with "monohydrochloride."

The present amendment is considered necessary for harmonization of dependent claims 15-17 with their independent claim 13. As originally filed, claims 15-17 recited "moxifloxacin monohydrate," while independent claim 13 recited "moxifloxacin monohydrochloride." The claim references to a monohydrate were inadvertent and are not in accord with the specification. Unfortunately, this error was not previously noted.

The Notice of Allowability that was mailed on January 22, 2007 stated that the allowed claims are 1, 6-13, 15-18, 21 and 33. This did not address pending claims 22-32, and applicants presume that the allowed claims were intended to include all of claims 21-33. Please advise if this presumption is not correct.

If there are any questions or issues to be resolved in connection with this submission, please contact the undersigned.

Respectfully submitted,

/R. A. Franks/

Robert A. Franks
Reg. No. 28,605
Attorney for Applicants

April 20, 2007

Dr. Reddy's Laboratories, Inc.
200 Somerset Corporate Blvd., Seventh Floor
Bridgewater, New Jersey 08807-2862
Telephone 908-203-6504
Facsimile 908-203-6515